Trial · NCT03741530
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of death or major disability | 90 days after the onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
| Secondary | The change in the volume of ICH from the initial to follow-up CT scans | 3 days after onset | |
| Secondary | The change in the volume of PHE from the initial to follow-up CT scans | 3 days after onset | |
| Secondary | The change in the volume of ICH from the initial to follow-up CT scans | 7 days after onset | |
| Secondary | The change in the volume of PHE from the initial to follow-up CT scans | 7 days after onset | |
| Secondary | The proportion of death or major disability | 3 days after onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
| Secondary | National Institute of Health stroke scale | 3 days after onset | The National Institutes of Health Stroke Scale (NIHSS) is used by healthcare providers to evaluate the impairment caused by stroke. The total score of the scale runs from 0 to 42. The higher score is an indicative of more severe impairment. |
| Secondary | Glasgow Coma Scale | 3 days after onset | The Glasgow Coma Scale is a scale for measuring the conscious state of patients with neurological diseases. The total score of the scale runs from 3 (deep coma or death) to 15 (fully awake person). |
| Secondary | Barthel Index | 3 days after onset | The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life. |
| Secondary | The proportion of death or major disability | 7 days after onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
| Secondary | National Institute of Health stroke scale | 7 days after onset | The National Institutes of Health Stroke Scale (NIHSS) is used by healthcare providers to evaluate the impairment caused by stroke. The total score of the scale runs from 0 to 42. The higher score is an indicative of more severe impairment. |
| Secondary | Glasgow Coma Scale | 7 days after onset | The Glasgow Coma Scale is a scale for measuring the conscious state of patients with neurological diseases. The total score of the scale runs from 3 (deep coma or death) to 15 (fully awake person). |
| Secondary | Barthel Index | 7 days after onset | The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life. |
| Secondary | Barthel Index | 90 days after onset | The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life. |
| Other | Incidence of hypoglycemia | 7 days after admission | Blood glucose \<3.1 mmol/L |
| Other | Incidence of symptomatic hypoglycemia | 7 days after admission | Blood glucose \<3.1 mmol/L with investigator-identified hypoglycemic symptoms |
| Other | Incidence of cardiac-related Adverse Events and Serious Adverse Events | 7 days after admission | |
| Other | Incidence of all-cause mortality | 90 days after onset | |
| Other | Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | During hospitalization |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03741530/registered